Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
life sciences
national blog main
5
×
boston blog main
boston
boston top stories
fda
san diego blog main
san diego top stories
san francisco blog main
clinical trials
deals
national top stories
new york blog main
new york top stories
san francisco top stories
startups
vc
abide therapeutics
accent therapeutics
aducanumab
akouos
allergan
alzheimer's disease
amblyotech
amylin pharmaceuticals
asklepios biopharmaceutical
astellas pharmaceuticals
azacitidine
ben cravatt
beta-thalassemia
bioeurope
biogen
biomarin pharmaceutical
biotech ipos
botox
boulder/denver blog main
boulder/denver top stories
brainvectis
bristol-myers squibb
What
developing
5
×
medicines
5
×
therapeutics
ipo
drug
fda
new
treat
abide
activity
affects
aims
americans
appointed
approach
approvals
approved
based
bio
biogen
biotech
brings
called
chief
clamped
company
covid
date
debuts
delays
diseases
disorders
drugs
dyne
dyne’s
economic
epigenetic
epigenetics
executive
fast
Language
unset
Current search:
" national blog main "
×
medicines
×
developing
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
5 years ago
Former Zavante Executive Tapped as Abide Therapeutics President
